

Author Index Volume 2 (2016)

The issue number is given in front of the pagination

- Abe, T., see Osawa, T. (2) 251–261
Aben, K.K., see Grotenhuis, A.J. (1) 77–89
Abida, W., M.I. Milowsky, I. Ostrovnaya, S.R. Gerst, J.E. Rosenberg, M.H. Voss, A.B. Apolo, A.M. Regazzi, A.S. McCoy, M.E. Boyd and D.F. Bajorin, Phase I Study of Everolimus in Combination with Gemcitabine and Split-Dose Cisplatin in Advanced Urothelial Carcinoma (1) 111–117
Abrams, J.S., see Lerner, S.P. (2) 165–202
Agarwal, P., see Kamat, A.M. (2) 203–213
Ahmed, O., see Boström, P.J. (1) 101–109
Al-Ahmadie, H., see Lerner, S.P. (2) 165–202
Allen, E.V., see Lerner, S.P. (2) 165–202
Amiri, A.T., see Lerner, S.P. (2) 165–202
Apolo, A.B., see Abida, W. (1) 111–117
Apolo, A.B., see Lerner, S.P. (2) 165–202

Badr, H., see Mohamed, N.E. (2) 139–149
Bagrodia, A., see Passoni, N.M. (1) 91–99
Bajorin, D.F., see Abida, W. (1) 111–117
Bajorin, D.F., see Lerner, S.P. (2) 165–202
Bamias, A., see Leiter, A. (3) 341–349
Bellmunt, J., see Lerner, S.P. (2) 165–202
Bellmunt, J., see Rose, T.L. (4) 405–413
Berry, D., see Mohamed, N.E. (2) 139–149
Bhat, A., M. Mokou, J. Zoidakis, V. Jankowski, A. Vlahou and H. Mischak, BcCluster: A Bladder Cancer Database at the Molecular Level (1) 65–76
Bidnur, S., R. Savdie and P.C. Black, Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer (1) 15–25
Bivalacqua, T., see Kamat, A.M. (2) 203–213
Bivalacqua, T.J., see Kaye, D.R. (2) 225–234
Black, P.C., see Bidnur, S. (1) 15–25
Boorjian, S.A., see Gershman, B., (1) 1–14
Boormans, J.L. and E.C. Zwarthoff, Limited Funds for Bladder Cancer Research and What Can We Do About It (1) 49–51
Boormans, J.L., see van Kessel, K.E.M. (3) 351–360

Borza, T., see Russell, C.M. (4) 381–394
Boström, P.J., J. Thoms, J. Sykes, O. Ahmed, A. Evans, B.W.G. van Rhijn, T. Mirtti, O. Stakhovskiy, M. Laato, D. Margel, M. Pintilie, C. Kuk, M. Milosevic, A.R. Zlotta and R.G. Bristow, Hypoxia Marker GLUT-1 (Glucose Transporter 1) is an Independent Prognostic Factor for Survival in Bladder Cancer Patients Treated with Radical Cystectomy (1) 101–109
Boström, P.J., T. Mirtti, B. van Rhijn, N.E. Fleshner, A. Finelli, M. Laato, M.A. Jewett, M.J. Moore, S. Sridhar, M. Nurmi, I.F. Tannock and A.R. Zlotta, Benefit of Adjuvant Chemotherapy and Pelvic Lymph Node Dissection in pT3 and Node Positive Bladder Cancer Patients Treated with Radical Cystectomy (2) 263–272
Boyd, M.E., see Abida, W. (1) 111–117
Brandt, A., see Hoffmann, M.J. (4) 449–463
Bristow, R.G., see Boström, P.J. (1) 101–109
Bryan, R.T., see D’Costa, J.J. (3) 301–317
Bulbul, M., see Shahait, M. (4) 467–468
Burkhard, F.C., see Kiss, B. (1) 53–59

Callahan, M., see Lerner, S.P. (2) 165–202
Canner, J.K., see Kaye, D.R. (2) 225–234
Cappelletti, V., see Fina, E. (4) 395–403
Casey, M.F., J. Wisnivesky, V.H. Le, U. Sarpel, K.D. Stensland, W.K. Oh and M.D. Galsky, The Relationship between Centralization of Care and Geographic Barriers to Cystectomy for Bladder Cancer (3) 319–327
Cha, E.K., see Lerner, S.P. (2) 165–202
Chan, K.S., see Lerner, S.P. (1) 37–47
Chandrasekar, T., N. Pugashetti, B. Durbin-Johnson, M.A. Dall’Era, C.P. Evans, R.W. deVere White and S.A. Yap, Effect of Neoadjuvant Chemotherapy on Renal Function following Radical Cystectomy: Is there a Meaningful Impact? (4) 441–448
Chisolm, S., see Kamat, A.M. (2) 203–213
Choudhury, A., see Mirza, A. (2) 151–163

- Chowdhury, S., see Rose, T.L. (4) 405–413
 Colecchia, M., see Fina, E. (4) 395–403
 Cookson, M., see Kamat, A.M. (2) 273–278
 Créhange, G., see Rose, T.L. (4) 405–413
- D'Costa, J.J., J.C. Goldsmith, J.S. Wilson, R.T. Bryan and D.G. Ward, A Systematic Review of the Diagnostic and Prognostic Value of Urinary Protein Biomarkers in Urothelial Bladder Cancer (3) 301–317
 Daidone, M.G., see Fina, E. (4) 395–403
 Dall'Era, M.A., see Chandrasekar, T. (4) 441–448
 Daneshmand, S., see Kamat, A.M. (2) 203–213
 Danna, B.J., M.J. Metcalfe, E.L. Wood and J.B. Shah, Assessing Symptom Burden in Bladder Cancer: An Overview of Bladder Cancer Specific Health-Related Quality of Life Instruments (3) 329–340
 de Haan, L.M., see van Kessel, K.E.M. (3) 351–360
 de Wit, R., see van Kessel, K.E.M. (3) 351–360
 Deal, A.M., see Rose, T.L. (4) 405–413
 DeCastro, G.J., see Sui, W. (4) 415–423
 deVere White, R.W., see Chandrasekar, T. (4) 441–448
 Dinney, C.P., see Lerner, S.P. (2) 165–202
 Doroshow, J.H., see Kamat, A.M. (2) 203–213
 Doucette, J., see Leiter, A. (3) 341–349
 Douglass, L. and M. Schoenberg, The Future of Intravesical Drug Delivery for Non-Muscle Invasive Bladder Cancer (3) 285–292
 Downs, T., see Mohamed, N.E. (2) 139–149
 Drake, C., see Lerner, S.P. (2) 165–202
 Dudek, A.M., see Grotenhuis, A.J. (1) 77–89
 Dunn, R.L., see Luckenbaugh, A.N. (2) 235–240
 Durbin-Johnson, B., see Chandrasekar, T. (4) 441–448
- Ecke, T., see Leiter, A. (3) 341–349
 Efsthathiou, J.A., see Kamat, A.M. (2) 203–213
 Efsthathiou, J.A., see Lerner, S.P. (2) 165–202
 Englesbe, M.J., see Luckenbaugh, A.N. (2) 235–240
 Erlmeier, F., A.K. Seitz, G. Hatzichristodoulou, L. Stecher, M. Retz, J.E. Gschwend, W. Weichert, H.R. Kübler and T. Horn, The Role of PD-L1 Expression and Intratumoral Lymphocytes in Response to Perioperative Chemotherapy for Urothelial Carcinoma (4) 425–432
 Evans, A., see Boström, P.J. (1) 101–109
 Evans, C.P., see Chandrasekar, T. (4) 441–448
- Fahmy, O., see Gakis, G. (3) 293–300
 Fahmy, O., see Godoy, G. (2) 127–137
- Fina, E., A. Necchi, P. Giannatempo, M. Colecchia, D. Raggi, M.G. Daidone and V. Cappelletti, Clinical Significance of Early Changes in Circulating Tumor Cells from Patients Receiving First-Line Cisplatin-Based Chemotherapy for Metastatic Urothelial Carcinoma (4) 395–403
 Finelli, A., see Boström, P.J. (2) 263–272
 Fleshner, N.E., see Boström, P.J. (2) 263–272
 Francis, F., see Passoni, N.M. (1) 91–99
 Fransen van de Putte, E.E., see van Kessel, K.E.M. (3) 351–360
 Friedman, J.F., see Luckenbaugh, A.N. (2) 235–240
 Fulkerson, C.M., see Knapp, D.W. (2) 241–250
- Gakis, G. and O. Fahmy, Systematic Review and Meta-Analysis on the Impact of Hexaminolevulinate-Versus White-Light Guided Transurethral Bladder Tumor Resection on Progression in Non-Muscle Invasive Bladder Cancer (3) 293–300
 Gakis, G., see Godoy, G. (2) 127–137
 Galsky, M., see Kamat, A.M. (2) 203–213
 Galsky, M.D., see Casey, M.F. (3) 319–327
 Galsky, M.D., see Leiter, A. (3) 341–349
 Galsky, M.D., see Rose, T.L. (4) 405–413
 Gershman, B., S.A. Boorjian and R.E. Hautmann, Management of T1 Urothelial Carcinoma of the Bladder: What Do We Know and What Do We Need To Know? (1) 1–14
 Gerst, S.R., see Abida, W. (1) 111–117
 Giannatempo, P., see Fina, E. (4) 395–403
 Gilbert, F., see Mohamed, N.E. (2) 139–149
 Gilbert, S.M., see Luckenbaugh, A.N. (2) 235–240
 Gills, J., see Zuk, K. (4) 433–439
 Given, B., see Mohamed, N.E. (2) 139–149
 Godoy, G., O. Fahmy, C.L. Smith and G. Gakis, Effects of Androgen and Estrogen Receptor Signaling Pathways on Bladder Cancer Initiation and Progression (2) 127–137
 Goldsmith, J.C., see D'Costa, J.J. (3) 301–317
 Groshen, S., see Lerner, S.P. (2) 165–202
 Grossman, H.B., see Kamat, A.M. (2) 273–278
 Grotenhuis, A.J., A.M. Dudek, G.W. Verhaegh, K.K. Aben, J.A. Witjes, L.A. Kiemeny and S.H. Vermeulen, Independent Replication of Published Germline Polymorphisms Associated with Urinary Bladder Cancer Prognosis and Treatment Response (1) 77–89
 Gschwend, J.E., see Erlmeier, F. (4) 425–432
- Hafez, K.S., see Osawa, T. (2) 251–261
 Hahn, N., see Leiter, A. (3) 341–349

- Hahn, N.M., see Lerner, S.P. (2) 165–202
- Hansel, D., see Lerner, S.P. (2) 165–202
- Harshman, L.C., see Rose, T.L. (4) 405–413
- Hatzichristodoulou, G., see Erlmeier, F. (4) 425–432
- Hautmann, R.E., see Gershman, B., (1) 1–14
- Hoadley, K.A., see Lerner, S.P. (1) 37–47
- Hoffmann, M.J., E. Koutsogiannouli, M.A. Skowron, M. Pinkerneil, G. Niegisch, A. Brandt, S. Stepanow, H. Rieder and W.A. Schulz, The New Immortalized Uroepithelial Cell Line HBLAK Contains Defined Genetic Aberrations Typical of Early Stage Urothelial Tumors (4) 449–463
- Höglund, M., see Lerner, S.P. (1) 37–47
- Hollenbeck, B.K., see Luckenbaugh, A.N. (2) 235–240
- Hollenbeck, B.K., see Osawa, T. (2) 251–261
- Hollingsworth, J.M., see Luckenbaugh, A.N. (2) 235–240
- Holzbeierlein, J.M., see Zuk, K. (4) 433–439
- Honkisz, S.I., see Knapp, D.W. (2) 241–250
- Horn, T., see Erlmeier, F. (4) 425–432
- Iyer, G., see Kamat, A.M. (2) 203–213
- Izawa, J., see Power, N.E. (1) 27–36
- James, M.B., see Sui, W. (4) 415–423
- Jankowski, V., see Bhat, A. (1) 65–76
- Jarow, J., see Lerner, S.P. (2) 165–202
- Jensen, D., see Zuk, K. (4) 433–439
- Jewett, M.A., see Boström, P.J. (2) 263–272
- Kamat, A., see Lerner, S.P. (2) 165–202
- Kamat, A.M., M. Cookson, J.A. Witjes, A. Stenzl and H.B. Grossman, The Impact of Blue Light Cystoscopy with Hexaminolevulinat (HAL) on Progression of Bladder Cancer – A New Analysis (2) 273–278
- Kamat, A.M., P. Agarwal, T. Bivalacqua, S. Chisolm, S. Daneshmand, J.H. Doroshov, J.A. Efsthathiou, M. Galsky, G. Iyer, W. Kassouf, J. Shah, J. Taylor, S.B. Williams, D.Z. Quale and J.E. Rosenberg, Collaborating to Move Research Forward: Proceedings of the 10th Annual Bladder Cancer Think Tank (2) 203–213
- Kapur, P., see Passoni, N.M. (1) 91–99
- Kassouf, W., see Kamat, A.M. (2) 203–213
- Kates, M., see Kaye, D.R. (2) 225–234
- Kaye, D.R., J.K. Canner, M. Kates, M.P. Schoenberg and T.J. Bivalacqua, Do African American Patients Treated with Radical Cystectomy for Bladder Cancer have Worse Overall Survival? Accounting for Pathologic Staging and Patient Demographics Beyond Race Makes a Difference (2) 225–234
- Kiemeney, L.A., see Grotenhuis, A.J. (1) 77–89
- Kim, W., see Lerner, S.P. (2) 165–202
- Kim, W.Y., see Lerner, S.P. (1) 37–47
- Kiss, B. and B. Roth, Reply from Authors to the Editorial Comment (1) 63–64
- Kiss, B., M. Paerli, D. Schöndorf, F.C. Burkhard, G.N. Thalmann and B. Roth, Pelvic Lymph Node Dissection may be Limited on the Contralateral Side in Strictly Unilateral Bladder Cancer without Compromising Oncological Radicality (1) 53–59
- Knapp, D.W., A. Ruple-Czerniak, J.A. Ramos-Vara, J.F. Naughton, C.M. Fulkerson and S.I. Honkisz, A Nonselective Cyclooxygenase Inhibitor Enhances the Activity of Vinblastine in a Naturally-Occurring Canine Model of Invasive Urothelial Carcinoma (2) 241–250
- Knauer, C., see Mohamed, N.E. (2) 139–149
- Knowles, M., see Lerner, S.P. (2) 165–202
- Koutsogiannouli, E., see Hoffmann, M.J. (4) 449–463
- Krege, S., see Leiter, A. (3) 341–349
- Kübler, H.R., see Erlmeier, F. (4) 425–432
- Kuk, C., see Boström, P.J. (1) 101–109
- Kwiatkowski, D., see Lerner, S.P. (2) 165–202
- Laato, M., see Boström, P.J. (1) 101–109
- Laato, M., see Boström, P.J. (2) 263–272
- Ladoire, S., see Rose, T.L. (4) 405–413
- Le, V.H., see Casey, M.F. (3) 319–327
- Lebastchi, A.H., see Russell, C.M. (4) 381–394
- Lee, C.T., see Luckenbaugh, A.N. (2) 235–240
- Lee, C.T., see Mohamed, N.E. (2) 139–149
- Lee, C.T., see Osawa, T. (2) 251–261
- Lee, E.K., see Zuk, K. (4) 433–439
- Leiter, A., J. Doucette, S. Krege, C.-C. Lin, N. Hahn, T. Ecke, G. Sonpavde, A. Bamias, W.K. Oh and M.D. Galsky, Obesity and Outcomes in Patients with Metastatic Urothelial Carcinoma (3) 341–349
- Lerner, S.P., D.F. Bajorin, C.P. Dinney, J.A. Efsthathiou, S. Groshen, N.M. Hahn, D. Hansel, D. Kwiatkowski, M. O’Donnell, J. Rosenberg, R. Svatek, J.S. Abrams, H. Al-Ahmadie, A.B. Apolo, J. Bellmunt, M. Callahan, E.K. Cha, C. Drake, J. Jarow, A. Kamat, W. Kim, M. Knowles, B. Mann, L. Marchionni, D. McConkey, L. McShane, N. Ramirez, A. Sharabi, A.H. Sharpe, D. Solit, C.M. Tangen, A.T. Amiri, E.V. Allen, P.J. West, J.A. Witjes and D.Z. Quale, Summary

- and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer (2) 165–202
- Lerner, S.P., D.J. McConkey, K.A. Hoadley, K.S. Chan, W.Y. Kim, F. Radvanyi, M. Höglund and F.X. Real, Bladder Cancer Molecular Taxonomy: Summary from a Consensus Meeting (1) 37–47
- Lin, C.-C., see Leiter, A. (3) 341–349
- Liontos, M., see Rose, T.L. (4) 405–413
- Lopez-Corona, E., see Zuk, K. (4) 433–439
- Lotan, Y., see Passoni, N.M. (1) 91–99
- Luckenbaugh, A.N., B.K. Hollenbeck, J.S. Montgomery, C.T. Lee, S.M. Gilbert, R.L. Dunn, J.F. Friedman, M.J. Englesbe, S.C. Wang and J.M. Hollingsworth, Using Analytic Morphomics to Understand Short-Term Convalescence after Radical Cystectomy (2) 235–240
- Mann, B., see Lerner, S.P. (2) 165–202
- Marchionni, L., see Lerner, S.P. (2) 165–202
- Margel, D., see Boström, P.J. (1) 101–109
- Matulay, J.T., see Sui, W. (4) 415–423
- McConkey, D., see Lerner, S.P. (2) 165–202
- McConkey, D.J., see Lerner, S.P. (1) 37–47
- McCoy, A.S., see Abida, W. (1) 111–117
- McShane, L., see Lerner, S.P. (2) 165–202
- Mehrazin, R., see Mohamed, N.E. (2) 139–149
- Messing, E.M., Checkpoint Inhibitors for Advanced Bladder Cancer (4) 473–474
- Metcalf, M.J., see Danna, B.J. (3) 329–340
- Milosevic, M., see Boström, P.J. (1) 101–109
- Milowsky, M.I., see Abida, W. (1) 111–117
- Mirtti, T., see Boström, P.J. (1) 101–109
- Mirtti, T., see Boström, P.J. (2) 263–272
- Mirza, A. and A. Choudhury, Bladder Preservation for Muscle Invasive Bladder Cancer (2) 151–163
- Mischak, H., see Bhat, A. (1) 65–76
- Mohamed, N.E., F. Gilbert, C.T. Lee, J. Sfakianos, C. Knauer, R. Mehrazin, H. Badr, D. Wittman, T. Downs, D. Berry, B. Given, P. Wiklund and G. Steineck, Pursuing Quality in the Application of Bladder Cancer Quality of Life Research (2) 139–149
- Mokou, M., see Bhat, A. (1) 65–76
- Montgomery, J.S., see Luckenbaugh, A.N. (2) 235–240
- Montgomery, J.S., see Osawa, T. (2) 251–261
- Moore, M.J., see Boström, P.J. (2) 263–272
- Morgan, T.M., see Osawa, T. (2) 251–261
- Morgan, T.M., see Russell, C.M. (4) 381–394
- Mott, S.L., see Steinberg, R.L. (2) 215–224
- Murai, S., see Osawa, T. (2) 251–261
- Nandagopal, L. and G. Sonpavde, Circulating Biomarkers in Bladder Cancer (4) 369–379
- Naughton, J.F., see Knapp, D.W. (2) 241–250
- Necchi, A., see Fina, E. (4) 395–403
- Niegisch, G., see Hoffmann, M.J. (4) 449–463
- Niegisch, G., see Rose, T.L. (4) 405–413
- Nurmi, M., see Boström, P.J. (2) 263–272
- O'Donnell, M., see Lerner, S.P. (2) 165–202
- O'Donnell, M.A., see Steinberg, R.L. (2) 215–224
- Oh, W.K., see Casey, M.F. (3) 319–327
- Oh, W.K., see Leiter, A. (3) 341–349
- Onyeji, I.C., see Sui, W. (4) 415–423
- Osawa, T., C.T. Lee, T. Abe, N. Takada, K.S. Hafez, J.S. Montgomery, A.Z. Weizer, B.K. Hollenbeck, T.A. Skolarus, S. Murai, N. Shinohara and T.M. Morgan, A Multi-Center International Study Assessing the Impact of Differences in Baseline Characteristics and Perioperative Care Following Radical Cystectomy (2) 251–261
- Ostrovnyaya, I., see Abida, W. (1) 111–117
- Paerli, M., see Kiss, B. (1) 53–59
- Passoni, N.M., S.F. Shariat, A. Bagrodia, F. Francis, V. Rachakonda, E. Xylinas, P. Kapur, A.I. Sagalowsky and Y. Lotan, Concordance in Biomarker Status Between Bladder Tumors at Time of Transurethral Resection and Subsequent Radical Cystectomy: Results of a 5-year Prospective Study (1) 91–99
- Pinkerneil, M., see Hoffmann, M.J. (4) 449–463
- Pintilie, M., see Boström, P.J. (1) 101–109
- Power, N.E. and J. Izawa, Comparison of Guidelines on Non-Muscle Invasive Bladder Cancer (EAU, CUA, AUA, NCCN, NICE) (1) 27–36
- Pugashetti, N., see Chandrasekar, T. (4) 441–448
- Quale, D.Z., see Kamat, A.M. (2) 203–213
- Quale, D.Z., see Lerner, S.P. (2) 165–202
- Rachakonda, V., see Passoni, N.M. (1) 91–99
- Radvanyi, F., see Lerner, S.P. (1) 37–47
- Raggi, D., see Fina, E. (4) 395–403
- Ramirez, N., see Lerner, S.P. (2) 165–202
- Ramos-Vara, J.A., see Knapp, D.W. (2) 241–250

- Real, F.X., see Lerner, S.P. (1) 37–47
 Regazzi, A.M., see Abida, W. (1) 111–117
 Retz, M., see Erlmeier, F. (4) 425–432
 Rieder, H., see Hoffmann, M.J. (4) 449–463
 Rose, T.L., A.M. Deal, S. Ladoire, G. Créhange, M.D. Galsky, J.E. Rosenberg, J. Bellmunt, A. Wimalasingham, Y.-N. Wong, L.C. Harshman, S. Chowdhury, G. Niegisch, M. Liontos, Patterns of Bladder Preservation Therapy Utilization for Muscle-Invasive Bladder Cancer (4) 405–413
 Rosenberg, J., see Lerner, S.P. (2) 165–202
 Rosenberg, J.E., see Abida, W. (1) 111–117
 Rosenberg, J.E., see Kamat, A.M. (2) 203–213
 Rosenberg, J.E., see Rose, T.L. (4) 405–413
 Roth, B., see Kiss, B. (1) 53–59
 Roth, B., see Kiss, B. (1) 63–64
 RoyChoudhury, A., see Sui, W. (4) 415–423
 Ruple-Czerniak, A., see Knapp, D.W. (2) 241–250
 Russell, C.M., A.H. Lebastchi, T. Borza, D.E. Spratt and T.M. Morgan, The Role of Transurethral Resection in Trimodal Therapy for Muscle-Invasive Bladder Cancer (4) 381–394
- Sagalowsky, A.I., see Passoni, N.M. (1) 91–99
 Sarpel, U., see Casey, M.F. (3) 319–327
 Savdie, R., see Bidnur, S. (1) 15–25
 Schoenberg, M., see Douglass, L. (3) 285–292
 Schoenberg, M.P., see Kaye, D.R. (2) 225–234
 Schöndorf, D., see Kiss, B. (1) 53–59
 Schulz, W.A., see Hoffmann, M.J. (4) 449–463
 Seitz, A.K., see Erlmeier, F. (4) 425–432
 Sfakianos, J., see Mohamed, N.E. (2) 139–149
 Shah, J., see Kamat, A.M. (2) 203–213
 Shah, J.B., see Danna, B.J. (3) 329–340
 Shahait, M. and M. Bulbul, Bladder Cancer Screening in Lebanese Population: There is Nothing more Unequal than the Equal Treatment of Unequal People (4) 467–468
 Sharabi, A., see Lerner, S.P. (2) 165–202
 Shariat, S.F., see Passoni, N.M. (1) 91–99
 Sharpe, A.H., see Lerner, S.P. (2) 165–202
 Shinohara, N., see Osawa, T. (2) 251–261
 Skolarus, T.A., see Osawa, T. (2) 251–261
 Skowron, M.A., see Hoffmann, M.J. (4) 449–463
 Smith, C.L., see Godoy, G. (2) 127–137
 Solit, D., see Lerner, S.P. (2) 165–202
 Soloway, M.S. Challenging Cases in Urothelial Cancer (4) 465–466
 Sonpavde, G., see Leiter, A. (3) 341–349
 Sonpavde, G., see Nandagopal, L. (4) 369–379
 Spratt, D.E., see Russell, C.M. (4) 381–394
- Sridhar, S., see Boström, P.J. (2) 263–272
 Stakhovskiy, O., see Boström, P.J. (1) 101–109
 Stecher, L., see Erlmeier, F. (4) 425–432
 Steinberg, R.L., L.J. Thomas, S.L. Mott and M.A. O'Donnell, Bacillus Calmette-Guérin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease (2) 215–224
 Steineck, G., see Mohamed, N.E. (2) 139–149
 Stensland, K.D., see Casey, M.F. (3) 319–327
 Stenzl, A., see Kamat, A.M. (2) 273–278
 Stepanow, S., see Hoffmann, M.J. (4) 449–463
 Sui, W., J.T. Matulay, M.B. James, I.C. Onyeji, M.C. Theofanides, A. RoyChoudhury, G.J. DeCastro and S. Wenske, Micropapillary Bladder Cancer: Insights from the National Cancer Database (4) 415–423
 Svatek, R., see Lerner, S.P. (2) 165–202
 Sykes, J., see Boström, P.J. (1) 101–109
- Takada, N., see Osawa, T. (2) 251–261
 Tangen, C.M., see Lerner, S.P. (2) 165–202
 Tannock, I.F., see Boström, P.J. (2) 263–272
 Taylor, J., see Kamat, A.M. (2) 203–213
 Thalmann, G.N., see Kiss, B. (1) 53–59
 Theofanides, M.C., see Sui, W. (4) 415–423
 Thomas, L.J., see Steinberg, R.L. (2) 215–224
 Thoms, J., see Boström, P.J. (1) 101–109
- van der Heijden, M.S., see van Kessel, K.E.M. (3) 351–360
 van Kessel, K.E.M., L.M. de Haan, E.E. Fransen van de Putte, B.W.G. van Rhijn, R. de Wit, M.S. van der Heijden, E.C. Zwarthoff and J.L. Boormans, Elevated Derived Neutrophil-to-Lymphocyte Ratio Corresponds With Poor Outcome in Patients Undergoing Pre-Operative Chemotherapy in Muscle-Invasive Bladder Cancer (3) 351–360
 van Rhijn, B., see Boström, P.J. (2) 263–272
 van Rhijn, B.W.G., see Boström, P.J. (1) 101–109
 van Rhijn, B.W.G., see van Kessel, K.E.M. (3) 351–360
 Verhaegh, G.W., see Grotenhuis, A.J. (1) 77–89
 Vermeulen, S.H., see Grotenhuis, A.J. (1) 77–89
 Vlahou, A., see Bhat, A. (1) 65–76
 Voss, M.H., see Abida, W. (1) 111–117
- Wang, S.C., see Luckenbaugh, A.N. (2) 235–240
 Ward, D.G. see D'Costa, J.J. (3) 301–317
 Weichert, W., see Erlmeier, F. (4) 425–432

- Weizer, A.Z., see Osawa, T. (2) 251–261
Wenske, S., see Sui, W. (4) 415–423
West, P.J., see Lerner, S.P. (2) 165–202
Wiklund, P., see Mohamed, N.E. (2) 139–149
Williams, S.B., see Kamat, A.M. (2) 203–213
Wilson, J.S., see D’Costa, J.J. (3) 301–317
Wimalasingham, A., see Rose, T.L. (4) 405–413
Wisnivesky, J., see Casey, M.F. (3) 319–327
Witjes, J.A., see Grotenhuis, A.J. (1) 77–89
Witjes, J.A., see Kamat, A.M. (2) 273–278
Witjes, J.A., see Lerner, S.P. (2) 165–202
Wittman, D., see Mohamed, N.E. (2) 139–149
Wong, Y.-N., see Rose, T.L. (4) 405–413
Wood, E.L., see Danna, B.J. (3) 329–340
Wyre, H., see Zuk, K. (4) 433–439
Xylinas, E., see Passoni, N.M. (1) 91–99
Yap, S.A., see Chandrasekar, T. (4) 441–448
Zlotta, A.R., see Boström, P.J. (1) 101–109
Zlotta, A.R., see Boström, P.J. (2) 263–272
Zoidakis, J., see Bhat, A. (1) 65–76
Zuk, K., D. Jensen, J. Gills, H. Wyre, J.M. Holzbeierlein, E. Lopez-Corona and E.K. Lee, The July Effect in Radical Cystectomy: Mortality, Morbidity, and Efficiency (4) 433–439
Zwarthoff, E.C., see Boormans, J.L. (1) 49–51
Zwarthoff, E.C., see van Kessel, K.E.M. (3) 351–360